PRASAD SUYASH (CMO and Head of R&D) sold 11.7% of their position (79K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $1.79M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−35.06K
Price / share
$23.74
Trade value
$832.23K
% of position
Common Stock
Shares
−3.86K
Price / share
$24.46
Trade value
$94.46K
% of position
Common Stock
Shares
−300.00
Price / share
$25.19
Trade value
$7.56K
% of position
Common Stock
Shares
−13.37K
Price / share
$21.42
Trade value
$286.47K
% of position
Common Stock
Shares
−6.20K
Price / share
$22.44
Trade value
$139.17K
% of position
Common Stock
Shares
−500.00
Price / share
$23.70
Trade value
$11.85K
% of position
Common Stock
Shares
−19.71K
Price / share
$21.12
Trade value
$416.19K
% of position
Net shares
−79K
Net value
-$1.79M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/29/2021 | S · Sale | −35.06K | $23.74 | $832.23K | 5.2% | 672.59K | 637.53K |
| Common Stock Direct | 6/29/2021 | S · Sale | −3.86K | $24.46 | $94.46K | 0.6% | 637.53K | 633.67K |
| Common Stock Direct | 6/29/2021 | S · Sale | −300.00 | $25.19 | $7.56K | 0.0% | 633.67K | 633.37K |
| Common Stock Direct | 6/30/2021 | S · Sale | −13.37K | $21.42 | $286.47K | 2.1% | 633.37K | 620K |
| Common Stock Direct | 6/30/2021 | S · Sale | −6.20K | $22.44 | $139.17K | 1.0% | 620K | 613.79K |
| Common Stock Direct | 6/30/2021 | S · Sale | −500.00 | $23.70 | $11.85K | 0.1% | 613.79K | 613.29K |
| Common Stock Direct | 7/1/2021 | S · Sale | −19.71K | $21.12 | $416.19K | 3.2% | 613.29K | 593.59K |
| Total | −79K | -$1.79M | ||||||